Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022 - ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...